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To guide decision making about driving ability, some patients with Parkinson’s disease 
(PD) undergo specialist driving assessment. However, decisions about driving safety in 
most patients need to be made without this definitive test. There is no consensus on 
what predicts unsafe driving in PD, nor a validated prediction tool to guide clinician 
decision making and the need to refer for further assessment.  
 
Objectives 
To describe the characteristics of PD patients assessed at a Driving Mobility Centre 
and investigate factors that predict driving assessment outcome. 
 
Methods 
Retrospective cohort study of PD patients assessed between 2012-2016. Descriptive 
analyses and logistic models to determine factors predicting a negative outcome.  
 
Results 
There were 86 assessments of PD patients. The mean age was 70 years (±9.2), 86% 
were male, median disease duration 7 years (Inter Quartile Range 5-12.5 years) and 
59% were referred by the DVLA. 62% had a negative “Not Drive” outcome. The 
Rookwood Driving Battery (RDB), depth of vision deficit, usual driving frequency, age, 
duration license held and response time were all predictors in univariable analysis. 
The RDB was the best predictor of assessment failure, conditional on other variables 
in a backward stepwise model (OR 1.29, 95% CI 1.05, 1.60, p=0.015). 
 
Conclusions 
This is the first study to describe PD patients undergoing driving assessments in the 
UK. In this population, RDB performance was the best predictor of outcome. Future 
prospective studies are required to better determine predictors of driving ability, to 





Parkinson’s disease (PD) is a common and complex neurodegenerative disorder 
causing physical, cognitive, and visual impairments. These impairments include 
bradykinesia, rigidity, tremor, freezing, poor attention, and impaired visuo-spatial 
awareness. Such impairments affect driving performance on standardised road tests 
[1-3], driving simulator experiments [3-5,11] and lead to increased crashes [7, 12]. 
High rates of driving cessation in PD [6-8] leads to greater inactivity, social isolation, 
depression, and caregiver burden [9, 10].  
 
Accurate assessment of driving ability in PD is needed to ensure road safety and 
prevent premature driving cessation. In the UK, some patients undergo specialist 
driving assessments at 20 Driving Mobility Centres [13, 14] following self-referral or 
referral from clinicians and various agencies including the Driver and Vehicle Licensing 
Agency (DVLA). Driving assessments involve off- and on-road components. The gold-
standard on-road driving assessment is time and resource intensive so not available 
to all patients. Off-road assessments, such as the Rookwood Driving Battery, have 
therefore been developed to predict on-road driving ability, through testing cognitive 
domains required for safe driving [15, 16]. At present, the driving assessment 
outcome remains a global impression of the patient’s ability in both off- and on-road 
components [17]. 
 
Although the final decision about license status lies with the DVLA, clinicians caring for 
patients with PD are faced with practically managing decisions about driving ability. 
Clinician experience alone cannot predict driving ability [2], yet only a minority of 
patients are undergoing definitive assessments. There is currently no validated 
prediction tool to guide clinicians about the thresholds in impairments which make 
driving unsafe or when to refer for driving assessment. The characteristics of those 
patients who are referred for assessment is also unknown.  
 
Developing a clinical prediction tool requires understanding of which disease features 
predict driving impairment. To date, studies examining predictors of driving ability in 
 
  
PD have used small sample sizes, varying neuropsychological tests and disease rating 
scales, and have lacked controls, resulting in a weak evidence base and no consensus 
[18]. 
 
The aims of this study were to a) describe the characteristics of patients with PD 
assessed at a Driving Mobility Centre and b) investigate which factors were predictors 





This is a retrospective cohort study of patients with idiopathic PD assessed at the 
Driving and Mobility Centre (West of England), The Vassall Centre, Bristol, UK.  This 
Centre serves a population of 1,696,604 people. 
 
Data collection 
A systematic search of all records at the Driving Centre was undertaken, and 
identified 2,082 assessments conducted between Oct 1, 2012 and Dec 31, 2016. 
Following screening of the referral letter for a diagnosis of idiopathic PD, 1,976 of 
these assessments were excluded. 5 withdrew before assessment was undertaken. 15 
secondary assessments of the same patient were also excluded. Data from 86 







Figure 1: Exclusion and inclusion of patients during the study period and summary of 
data collected.  PD = Parkinson’s disease.  
 
Data for each patient were extracted from paper records held at the Driving Centre 
(please see Figure 1 and Appendix 1 in the supplementary data on the journal website 
(www.academic.oup.com/ageing)). Cognition was determined from either Montreal 
Cognitive Assessment (MoCA) [19] or Rookwood Driving Battery (RDB) [16]. Each of 
the 12 subtests of the RDB are given a score of 0 (pass), 1 (borderline), 2 (fail). These 
scores are totaled to give the overall battery score ranging from 0-22, with a higher 
score representing a worse performance [16]. The outcome of the driving assessment 
was recorded as ‘drive’ or ‘not drive’.  
 
All participants consented at the time of assessment for their data to be used for 
research purposes. Ethical approval was granted by the University of Bristol Ethics 
 
  
Committee on 15/01/2017 and institutional approval from the Driving Mobility Board 
on 17/02/2017. 
 
Statistical methods  
Variables were described using the mean (SD) if normally distributed and median 
(interquartile range IQR) if skewed. Categorical variables were described as frequency 
and percentage. Associations between characteristics and driving assessment 
outcome were assessed using univariable logistic regression. From this, candidate 
predictors, with a p-value of <0.05, were included in a backward stepwise 
multivariable logistic regression model [20]. Starting with all candidate variables, this 
model iterates so that at each step the variable with the largest p-value ≥ 0.05 is 
removed, continuing until no variables with p-values ≥ 0.05 remain. All analyses were 





Patient, disease, and driving characteristics 
The patient’s disease and driving characteristics are summarised in Table 1. The mean 
age was 70 years old (±9.2) and the majority of subjects were male (86%). Most had 
been referred for assessment by the DVLA (59%), held a full license (47%) and drove a 
manual transmission vehicle (55%). Most participants were only driving in the local 
area (47%) and had been driving in the last 6 days (69%). Equal proportions were 




     
Table 1: Patient, disease, driving characteristics and univariable logistic regression 
(summary version – please see Appendix 2 in the supplementary data on the journal 
website for full version (www.academic.oup.com/ageing)). Data are n (%), mean 
(±SD), median (IQR). OR = odds ratio, CI = 95% confidence interval, P = p value, DVLA 
= Driver and Vehicle Licensing Agency, GP = General practitioner, Section 88 = Section 
88 of Road Traffic Act 1988, PD = Parkinson’s disease, RDB = Rookwood Driving 




The median disease duration was 7 (IQR 5-12.5) years. The RDB was the predominant 
cognitive test used (67%). The average RDB score was 6 (IQR 2-9). The majority of 
subjects did not demonstrate a depth of vision (53%) nor visual field deficit (66%). The 
median lowest contrast sensitivity seen was 20% (IQR 10-20) and 71% of subjects 
passed the glare recovery test. Median response time was 0.60 seconds (IQR 0.51-
0.68). The assessment outcome was mostly negative with 63% of participants given a 
‘not drive’ outcome. 
 
Relationship between characteristics and driving assessment outcome  
Age, duration license held, overall RDB score, usual driving distance, depth of vision 
deficit and response time were found to be significantly different between 
assessment outcome groups. On inclusion of these candidate variables in a backwards 
stepwise logistic regression, the RDB overall score was found to be the best predictor 
of driving assessment failure, conditional on the other variables (OR 1.29, 95% CI 1.05, 




Our results show that patients with PD undergoing driving assessment are mostly 
men, with a mean age of 70 and disease duration of 7 years. They are experienced 
drivers who drive regularly but locally. Most assessments result in people no longer 
being able to drive. The RDB is the most commonly used cognitive battery and RDB 
performance was the best predictor of driving assessment outcome in our population. 
With each point increase in the RDB score, the likelihood of no longer driving 
increased by 45%. Increasing age, presence of a depth of vision deficit, shorter usual 
driving distance and increased response times were also found to predict test failure.  
 
To the best of our knowledge, this is the first study to provide real-world data on 
patients with PD collected during specialist driving assessments. The demographic 
characteristics we describe are similar to those of community dwelling PD patients 
[22] and to a previous meta-analysis of studies examining driving in PD [23]. However, 
 
  
the large proportion of negative assessment outcomes seen in our study differs from 
previous experimental studies which found that the majority of subjects were safe to 
continue driving [18, 24]. This difference is likely to represent a selection bias for 
more impaired patients referred for assessment at Driving Mobility centres than 
those recruited as study participants. Understanding what prompted their referral 
and at what threshold could guide future work developing a clinical driving prediction 
tool.   
 
Our finding that cognitive impairment is the biggest predictor of poor driving ability is 
supported by the existing literature [18, 24, 25]. Cognitive testing should hence form 
a key component of a predictive tool of driving ability in PD. However, significant 
impairment in other symptom domains e.g. motor function, could deem driving 
unsafe despite good cognitive ability. For this reason, a predictive tool to guide 
clinicians should include screening within all domains predictive of driving ability. Due 
to differences in sample sizes, rating scales of predictors, outcome measures of 
driving ability and heterogeneous samples within the existing literature, there 
remains a weak evidence base of predictors to guide development of such a tool [18].  
 
This study is strengthened by its novelty, pragmatism and high number of records 
(>2000) screened over a 5-year period. However, there are several important 
limitations. Data obtained during driving assessments is non-standardised and so 
retrospective collection led to a degree of missing data. We based the diagnosis of PD 
on referral criteria and therefore patients with parkinsonism of other aetiologies may 
have been included. Our assessment of the value of the RDB in predicting a negative 
assessment outcome is likely to be biased, resulting in an over-estimation of its worth. 
This has arisen because this battery is part of the global impression used to decide 
assessment outcome. As a result, there is an element of circularity to assessing its 
predictive value, as the gold standard is not independent of the screening test. 
 
Future studies in a larger unselected population with prospective systematic data 
collection are now needed to better understand which disease characteristics predict 
driving ability in PD and the thresholds which render driving unsafe. This knowledge 
 
  
can guide the development of a clinical prediction tool to inform clinicians about 
driving prognosis, referral thresholds and assessment frequency.  
 
Key points 
1. There is a lack of evidence as to what predicts driving ability in Parkinson’s 
disease. 
2. Rookwood Driving Battery score was predictive of a negative driving 
assessment outcome in this retrospective study. 
3. Increasing age, license tenure, response time, depth of vision deficit and 
shorter driving distance were also predictive.  
4. Further prospective studies are required to better understand what governs 
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Driving in Parkinson’s Disease: A Retrospective Study of Driving and Mobility 
Assessments - Appendix 1: Further Methodology 
 
Disease factors collected included year of diagnosis and physical features recorded as 
the positive presence of the key features of PD including tremor, bradykinesia, 
postural instability, rigidity, freezing and falls history. As these data were not 
systematically collected nor validated tools utilised, we recorded data from multiple 
sources within the records including referral source, occupational therapist 
assessment, patient declared symptomology or declaration from family or friends. 
Vision was captured using the Keystone View Ophthalmic Telebinocular test battery 
which includes contrast sensitivity, glare recovery, depth of vision and visual fields. 
These domains were used to derive a binary score indicating presence or absence of 
depth of vision deficit and visual fields deficit.  Mean response time was derived from 
5 trials of a response time test, which involved a computer connected car and a mock 
set of brake lights, measuring time taken for the driver to respond to the stimulus and 
move their foot from the accelerator to the brake.  Response times were measured in 
seconds, with a greater time representing a worse performance. Driving 
characteristics included current license status and tenure, transmission of their 
normal driving vehicle (automatic or manual) and the duration of time since the 
patient had last driven. Usual driving distance was recorded as local; regional; 
national/international. Usual driving frequency was classified as daily; weekly; 
monthly; less than monthly or not determined. This was reclassified as more than 
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Supplementary Table 1: Patient disease and driving characteristics (full version). Data 
are n (%), mean (±SD), median (IQR). DVLA = Driver and Vehicle Licensing Agency, GP 
= General practitioner, Section 88 = Section 88 of Road Traffic Act 1988, PD = 
Parkinson’s disease, MoCA = Montreal cognitive assessment, RDB = Rookwood Driving 
Battery. Higher score indicates better performance,  Lower score indicates better 
performance.  
 
 
